Journal
Journal of experimental medicine
Publication Date
2-5-2024
Volume
221
Issue
2
First Page
e20231363
Document Type
Open Access Publication
DOI
10.1084/jem.20231363
Rights and Permissions
Mika P. Cadiz, Katelin A. Gibson, Kennedi T. Todd, David G. Nascari, Nashali Massa, Meredith T. Lilley, Kimberly C. Olney, Md Mamun Al-Amin, Hong Jiang, David M. Holtzman, John D. Fryer; Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med 5 February 2024; 221 (2): e20231363. © 2024 Cadiz et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20231363. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
Recommended Citation
Cadiz, Mika P; Gibson, Katelin A; Todd, Kennedi T; Nascari, David G; Massa, Nashali; Lilley, Meredith T; Olney, Kimberly C; Al-Amin, Md Mamun; Jiang, Hong; Holtzman, David M; and Fryer, John D, "Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations." Journal of experimental medicine. 221, 2. e20231363 (2024).
https://digitalcommons.wustl.edu/oa_4/2994
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
